Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | E542X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | PIK3CA E542X indicates any Pik3ca missense mutation that results in the replacement of the glutamic acid (E) at amino acid 542 by a different amino acid. |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA exon10 PIK3CA E542X |
Transcript | NM_006218.4 |
gDNA | chr3:g.179218294_179218296 |
cDNA | c.1624_1626 |
Protein | p.E542 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006218.3 | chr3:g.179218294_179218296 | c.1624_1626 | p.E542 | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179218294_179218296 | c.1624_1626 | p.E542 | RefSeq | GRCh38/hg38 |
XM_006713658.5 | chr3:g.179218294_179218296 | c.1624_1626 | p.E542 | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179218294_179218296 | c.1624_1626 | p.E542 | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179218294_179218296 | c.1624_1626 | p.E542 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT03842228 | Phase I | Copanlisib + Durvalumab + Olaparib | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations | Active, not recruiting | USA | 0 |